Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

OZEMPIC

SEMAGLUTIDE

Standard Dose
2MG/1.5ML (1.34MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OZEMPIC is listed in Drugs@FDA under application 209637 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SEMAGLUTIDE Form and strength SOLUTION;SUBCUTANEOUS - 2MG/1.5ML (1.34MG/ML) Sponsor NOVO Submission history Latest submission status date: 2025-10-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview OZEMPIC is listed in Drugs@FDA under application 209637 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SEMAGLUTIDE Form and strength SOLUTION;SUBCUTANEOUS - 2MG/1.5ML (1.34MG/ML) Sponsor NOVO Submission history Latest submission status date: 2025-10-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.